![Colony Capital Inc](/common/images/company/NY_CLNY-H.png)
NEW YORK, NY -- (Marketwire) -- 04/11/11 -- Regenicin, Inc. (OTCBB: RGIN) filed an 8-K on April 7th stating that they have received "combination product designation" by the FDA. As fewer...
Sanofi-Aventis (SNY) unit Genzyme will present results of phase II trials of its alemtuzumab multiple sclerosis treatment at an American Academy of Neurology meeting in Hawaii April 9 through...
We are maintaining our 'Neutral' recommendation on BioMarin Pharmaceutical Inc.(BMRN) with a target price of $27.00 following the release of fourth quarter and full-year 2010...
Cephalon Inc.'s (CEPH) rejection of a $5.7 billion takeover offer from Valeant Pharmaceuticals International Inc. (VRX) has put the future of Cephalon in the hands of its shareholders...
Sanofi-Aventis (SNY) recently announced the successful completion of its exchange offer for all outstanding shares of common stock of Genzyme Corporation (GENZ). With 224,528,469 shares of...
We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development...
French pharmaceutical Sanofi-Aventis SA (SAN.FR) Monday said it secured control of U.S. biotech firm Genzyme Corp. (GENZ) after a tender offer that expired on Friday. Sanofi-Aventis has secured...
Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation -- Company Announces Four-Day Subsequent Offer Period for Remaining Shareholders -- Genzyme Becomes a Subsidiary of...
("BlackRock To Join S&P 500 Index, Replacing Genzyme," at 5:53 p.m. EDT, misstated BlackRock stock's price and percentage change over the last year in the second paragraph. The correct version...
BlackRock Inc. (BLK) is slated to replace Genzyme Corp. (GENZ) in the S&P 500 index as the biotechnology company is set to be acquired, Standard & Poor's said Tuesday. Shares of BlackRock...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.